Presentations by Program

The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017 2019), geographically diverse drug resistant Enterobacterales isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, John Mueller and Alita Miller (Microbe, 2021)

The Novel β-lactamase Inhibitor ETX1317 Restores the Activity of Cefpodoxime Against Drug-Resistant Enterobacteriaceae

McLeod S, Carter N, Moussa S, Mueller J, Tommasi R and Miller A (Microbe 2019)

Cefpodoxime-ETX1317 Susceptibility is Unaffected by Ceftazidime-Avibactam Resistance Mutations V240G, D179Y and D179Y/T243M in KPC-3 β-Lactamase

Shapiro AB, Moussa SH, Carter NM, Gao N and Miller AA (Microbe 2019)

Efficacy of Cefpodoxime Proxetil and ETX0282 in a Murine UTI Model with E. coli and K. pneumoniae

Weiss WJ, Carter K, Pulse ME, Nguyen P, Valtierra D, Peterson K, Tommasi R, Mueller JP, O'Donnell J (ECCMID 2019)

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Recent Global Enterobacteriaceae Isolates from Urinary Tract Infections

McLeod S, Moussa S, Huband M, Mueller J, Tommasi R and Miller A (ECCMID 2019)

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Extended Spectrum β-lactamase (ESBL)- and Carbapenemase-Expressing Enterobacteriaceae Isolated From Recent Urinary Tract Infections

Sarah McLeod, ASM Microbe 2018

Cefpodoxime proxetil/ETX0282: A novel oral β-lactam/β-lactamase inhibitor combination to treat the emerging threat of multi-drug resistant Enterobacteriaceae

John O’Donnell, ASM Microbe 2017

The Antibacterial Activity of Cefpodoxime and the Novel β–lactamase Inhibitor ETX1317 Against Recent Clinical Isolates of β–lactamase-producing Enterobacteriaceae

Sarah McLeod, ASM Microbe 2017

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

Thomas Durand-Reville, ASM Microbe 2017